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Immunosuppression management in kidney transplantation has evolved to include an increasingly 
diverse choice of medications.  While informed by patient and donor characteristics, choice of 
immunosuppression regimen varies widely across transplant programs. Using a novel database 
integrating national transplant registry and pharmacy fill records, immunosuppression use 6-
12 and 12-24 months post-transplant was evaluated for 22,453 patients transplanted at 249 U.S. 
programs in 2005-2010. Use of triple immunosuppression comprising tacrolimus, mycophenolic 
acid or azathioprine, and steroids varied widely (0-100% of patients per program), as did use of 
steroid-sparing regimens (0-77%), in sirolimus-based regimens (0-100%) and cyclosporine-based 
regimens (0-78%). Use of triple therapy was more common in highly sensitized patients, women, 
and recipients with dialysis duration > 5 years. Sirolimus use appeared to diminish over the study 
period. Overall, patient and donor characteristics explained only a limited amount of the observed 
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immunosuppression. The majority of patients who received triple therapy (79%), cyclosporine-
based (87.6%) and sirolimus-based regimens (84.3%) continued these regimens in the second year 
post-transplant. This population-based study of immunosuppression practice demonstrates 






Advances in immunosuppression (ISx) have substantially reduced the risk of early acute 
cellular rejection (ACR) in patients undergoing immunologically compatible kidney 
transplantation.(1)  The incidence of ACR has declined despite an increased prevalence of highly 
sensitized patients, re-transplant recipients and the growing use of extended-criteria organs. 
Unfortunately, the marked reduction in ACR has come at the cost of rising rates of ISx-related 
complications including bacterial and viral infections (pneumonia, urinary tract infections, BK 
viruria), malignancy, and accelerated cardiovascular disease (2-5). Furthermore, long term survival 
remains limited by chronic transplant glomerulopathy (CTG), interstitial fibrosis/tubular atrophy, 
inflammation, and subclinical cellular and humoral rejection despite apparently effective ISx. (6, 7)    
 In addition to complications associated with a globally immunosuppressed state, specific 
agents have well described associations with metabolic and physiologic derangements. Tailoring 
immunosuppression based on patient characteristics, pharmacological side effects, and donor 
factors to balance these toxicities with the need to maintain effective and durable long-term ISx 
remains a key challenge for transplant professionals.(8-14) To develop an accurate assessment of 
current practices in the selection of maintenance ISx for kidney transplantation, we constructed a 
novel database integrating national transplant registry data with pharmacy fill records. Our 
primary goals were to examine associations of patient characteristics with regimen selection in a 
multi-level analytic framework and to quantify the contributions of center-level practice variation 
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Study data were constructed by linking OPTN records a large U.S. pharmaceutical claims data (PCD) 
clearinghouse. The OPTN data system includes data on all donor, wait-listed candidates, and 
transplant recipients in the U.S., submitted by the members of the OPTN, and has been described 
elsewhere (15). The Health Resources and Services Administration (HRSA), U.S. Department of 
Health and Human Services provides oversight to the activities of the OPTN contractor. The PCD 
comprises National Council for Prescription Drug Program 5.1-format prescription claims 
aggregated from multiple sources including data clearinghouses, retail pharmacies, and 
prescription benefit managers for approximately 60% of U.S. retail pharmacy transactions, 
including those reimbursed by private payers, public payers, and self-paid fills. After Institutional 
Review Board and HRSA approvals, PCD records from 2005 to 2010 were linked with OPTN records 
for kidney transplant recipients. Because of the large sample size, the anonymity of the patients 
studied, and the non-intrusive nature of the research, a waiver of informed consent was granted per 
the Department of Health and Human Services Code of Federal Regulations (Title 45, Part 46, 
Paragraph 46.116). Analyses were performed using Health Information Portability and 
Accountability Act (HIPAA) compliant limited datasets. This study was approved by the 
Institutional Review Board (IRB) of Saint Louis University.  
 
Eligible transplant recipients had an OPTN kidney transplant record and pharmacy claims during 
months 6 to 12 post-transplantation to allow ISx regimen stabilization. A subset of the primary 
sample who also had PCD data 12-24 months post-transplant were examined in a secondary 
analysis. ISx regimens were classified using PCD data into 6 mutually exclusive groups: Group 1 
(Reference): Standard triple therapy, defined as Tac with mycophenolic acid (mycophenolate 
mofetil, mycophenolate sodium), or azathioprine (MPA/AZA), and prednisone (Pred), 
“Tac+MPA/AZA+Pred”; Group 2: Corticosteroid-sparing, “Tac+MPA/AZA”; Group 3: MPA/AZA 
sparing, “Tac alone, Tac+Pred”;  Group 4: mTOR-based, defined by any fill for Sirolimus (SRL) as the 
mTOR available in the study period, with or without other agents including CNI, “SRL-based”; Group 
5: Cyclosporine (CsA)-based, defined by CsA without SRL, “CsA-based”; Group 6: “Other regimens” 
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To visually assess unadjusted variation in ISx regimen use at the center level across the U.S, the 
observed proportion of patients receiving each regimen was computed for each center and 
displayed as stacked bar plots.  
 
Combined Center and Case-Level modeling 
Bi-level hierarchical models were constructed to adjust for clustering effects: Level 1 comprised 
patient/donor and transplant (case) factors and Level 2 represented the center, wherein the use of 
each alternative regimen was compared individually to the reference regimen (pairwise).   
Empirical Bayes Estimates (EBE) provide the adjusted proportion (with 95% confidence intervals, 
CI) of use of a regimen of interest compared to the reference regimen, incorporating case-mix 
adjustment from the hierarchical model. If the 95% CI for a given center’s EBE of use a regimen of 
interest does not include the median national rate of use, this indicates a prescribing pattern that is 
statistically significantly different from the expected rate of use for that regimen.   
Heterogeneity in ISx prescribing across centers was quantified using intraclass correlation 
(ICC) and median odds ratios (MOR). ICC is defined as the ratio of cluster variance (center impact) 
to the total observed variance in ISx use, with contributions in our study framework defined as 
center-related, case-related, and other unmeasured impacts. In this context, the ICC quantifies the 
proportion of total variance in ISx use that is accounted for by center.  The MOR provides the 
median of the odds that patients with identical characteristics will receive the ISx regimen of 
interest when 2 centers are drawn at random (performed for all possible pairs of centers). For 
example, a MOR of 2.0 means that if we select centers at random across all centers, then a patient 
with a given set of characteristics is, on an average, twice as likely to receive the ISx regimen of 
interest at one of the randomly selected center than at the other selected center (16).  The adjusted 
odds ratios (aOR) of being placed on an ISx regimen other than standard triple therapy was 
determined for patient and donor factors, after accounting for the impact of center using the 
hierarchical model.   
Secondary analyses were performed in the subgroup with available serum creatinine data 
at 6-months for computation of 6-mo estimated glomerular filtration rate (eGFR). Estimated GFR 
was computed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (17).  
Data were analyzed using Stata 13, College Station, TX. Hierarchical logistic regression 
modeling was in Stata using the “xtmelogit” command with center as a random intercept. The ICC 
and the MOR were calculated using “xtmrho” (3rd
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Contributions of Case-Level Factors to Variation in ISx Use 
To quantify the degree that variance in ISx regimen use was explained by recipient and donor 
characteristics, we performed multivariate logistic regression modeling with ISx regimen as the 
dependent variable and case factors as the predictors. Pairwise models were constructed to assess 
the relative likelihood of utilizing each specific regimen (as outlined above) compared with 
standard triple drug therapy. 
 
Integrated PCD and registry data were available for 22,453 transplants performed at 249 centers in 
the study period. The study sample included 27% of all transplants performed. Compared to 
transplant recipients registered in the OPTN who were not captured in the PCD, the proportion of 
patients with private insurance (44% vs. 39% P<.001) and Caucasian race (59% vs. 53% p<.001) 
was increased in the study cohort ( ). Overall, 7.7% of patients experienced a reported acute 
rejection in the first 6 months post-transplant. Triple therapy (Tac+MPA/AZA+Pred) was the most 
frequently used regimen (33.8% patients overall), followed by steroid-sparing (Tac+MPA/AZA) in 
25.8%, MPA/AZA sparing (Tac alone, Tac+Pred) in 11.3%, SRL-based (with or without Tac/CSA) in 
9.9%, and CSA-based in 7.8%; other regimens were filled in 11.6% of the sample. The majority of 
patients in the SRL group were also receiving CNIs (Tac 37.5%, CSA 15.3%).  There was substantial 
variation in the unadjusted use of ISx regimens across centers ( ).  The use of triple ISx 
varied from 0-100% patients across transplant centers, steroid-sparing regimens (0-77%), SRL-
based (0-100%), CSA-based (0-78%), and other (0-100%). 
 
Patient characteristics were strongly correlated with differential use of maintenance ISx regimens 
6-12 months post-transplant ( ). Older patients were more likely to receive regimens without 
MPA/AZA than triple therapy: [age > 60 years (adjusted odds ratio [aOR] for MPA/AZA sparing: 
1.50, p<0.0001), 49-60 years old (aOR 1.20, P<0.01]. Compared with use in adults age 31-45, CSA-
based regimens were more commonly used in patients aged 49-60 years (aOR 1.43, p<0.0001) and 
especially in older patients >60 years (aOR 1.87, p<0.0001), and less likely to be used in younger 
adults 18-30 years (aOR 0.55, p<0.0001) and children aged <18 years old (aOR 0.42, p<0.0001).  
Patient -Level Correlates of ISx Regimen Use 
 Women were more likely to be maintained on triple ISx regimens than men. While ISx 
regimens were generally similar in African Americans compared with Caucasians, African 















This article is protected by copyright. All rights reserved 
less likely to receive Tac without MPA/AZA (aOR 0.85, p<0.05), or SRL-based therapies (aOR 0.84 
p<.05).  
 Prolonged ESRD was also associated with a higher use of “other” ISx regimens (aOR 1.25, 
p<0.01). Compared to diabetic patients, patients with glomerulonephritis as the cause of their ESRD 
were more likely to receive triple therapy. There was also a trend for greater use of steroid-sparing 
ISx in patients with polycystic kidney disease (aOR 1.16, p=0.08).  
 As expected, patients at a higher immunological risk for ACR, including those with prior 
transplantation, increasing levels of HLA mismatch, and higher PRA, were less likely to receive 
regimens other than the reference triple therapy.  For example, PRA >=80 was associated with less 
use of Tac+MPA/AZA (aOR 0.58, p<0.0001), Tac alone, Tac+Pred (aOR 0.80, p<0.04), SRL-based 
(aOR 0.61, p<0.0001), CSA-based (aOR 0.51, P<0.0001), or other (aOR 0.77, P<0.01) regimens. 
Induction therapy with depleting agents was associated with a higher use of steroid-sparing, 
MPA/AZA-sparing, and SRL-based regimens, while induction with IL-2R was associated with a 
statistically lower likelihood of receiving steroid-sparing and antimetabolite-sparing regimens. 
 Over time, there have been alterations in the ISx landscape which may in part reflect 
changes in case characteristics.  There was decreasing use of SRL use compared to reference ISx 
regimen (2006 vs 2005: aOR 0.53, p<0.0001; 2009 vs 2005: aOR 0.29, p<0.0001). Compared to 
recipients of transplants from standard criteria donors, recipients from living-related donors 
appear to have higher rates of receiving steroid-sparing regimens, Tac+MPA/AZA (aOR 1.34, 
p<0.0001), while recipients from ECD donors were more likely to receive SRL-based regimens (aOR 
1.73, p<0.0001). ISx regimen did not vary by donor race except that there was an increased use of 
“Tac alone, Tac+Pred” in recipients from “Other” race donors (aOR 1.27, p <0.01). Economic factors 
appeared to influence prescription patterns with cash payers appearing more likely to be taking 
“minimized” regimens, eg: Tac+MPA/AZA (aOR 1.43, p<0.0001); MPA/AZA-sparing (aOR 1.73, 
p<0.0001) and Other (aOR 1.69, p<0.0001) regimens.  Patients with a history of acute rejection in 
the first 6mo were less likely to receive a steroid-sparing (aOR 0.39, P<0.0001) or CsA-based (aOR 
0.64, P<0.01) regimen, subsequently, during mos 6-12 after transplant.  
 Associations between patient and donor characteristics and regimen choice during months 
6-12 post-transplant were also examined after adjusting for eGFR at 6 months in the sample with 
available data for eGFR computation (n=12,340). There were no changes in inferences across 
patient level characteristics. However, there was an association of SRL use with eGFR, such that SRL 
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ml/min/1.73 m2) but more increasingly common with lower eGFR 15-30 (aOR 2.84, p<0.0001) and 
< 15 ml/min/1.73 m2 (aOR 3.28, p<0.01). 
 
Among the subset of the primary sample who also had PCD data 12-24 months post-transplant 
(n=18,298), regimen selection in the second year was compared with the regimen at 6-12 months. 
Compared with initial regimen at 6-12 months, the proportion of patients on triple therapy 
increased from 33.8% to 37.7% in year two post-transplant ( S1). The majority of patients 
who received triple therapy (79%), CSA-based (87.6%) and SRL-based regimens (84.3%) continued 
these regimens in second year post-transplant ( S2). By comparison, only 55.8% of those on 
“other” regimens at year 1 remained on other regimens during year 2.  
Temporal Trends 
 
Hierarchical logistic regression models demonstrated that between-center variation in use 
of specific ISx regimens was significantly greater than what would be expected based on differences 
in patient demographics or transplant characteristics (p<0.0001). Based on EBE comparing the 
relative use of a specific alternative ISx regimens to triple therapy in two-way analyses, we 
identified 28% of centers in which frequency of Tac+MPA/AZA use was statistically higher than 
expected while 13% employed Tac alone, Tac+Pred at higher rates. ( ). Addition of 6-month 
eGFR in the model in secondary analysis reduced the variation in practice among centers (
). In the fully adjusted model, including eGFR at 6 months, 20.1% of centers prescribed 
Tac+MPA/AZA at rates significantly greater than expected.  Similarly, 19.6% of centers had 
statistically significantly greater use of SRL and 20.3 % of centers were higher than expected users 
of CSA-based regimens.  
Center-Driven Variation in Regimen Use 
Finally, the degree of heterogeneity in prescribing practice was assessed using the ICC. The 
ICCs for SRL, CSA and Tac+MPA/AZA regimens in models unadjusted for patient and donor 
characteristics were 0.40, 0.46 and 0.30 respectively, which supports that 40%, 46% and 30% of 
the variation in the use of the “non-standard” regimens was due to “center effect” ( 4). The 
ICCs remained similar even after adjustment for case factors. These ICC did not change over time 
when the sample was stratified into two eras. The MORs from case-factor adjusted models for each 
regimen compared with reference triple therapy ranged from 2.08 to 5.15. ( ).  Thus, a 
patient with a given set of characteristics was, on average, 4.4-times as likely to receive a SRL-based 















This article is protected by copyright. All rights reserved 
 
U  
Using a novel linkage of the national transplant registry data and a large pharmaceutical 
claims database, we identified substantial variation in the choice of maintenance ISx regimen after 
kidney transplantation.  Nationally, over one third of patients received triple maintenance ISx 6-12 
months post-transplant.  However, in some centers, 100% of patients, regardless of characteristics, 
were placed on triple therapy, whereas other centers used this regimen rarely if ever.  After 
adjustment of patient and donor characteristics, ISx use varied markedly across centers, with 2- to 
5-fold variation in the likelihood of use of non-triple therapy based regimens.   
Although case-level factors are a weaker determinant of regimen choice than center 
practice, we identified a number of clinically rational associations between ISx regimen selection 
and patient and donor characteristics. Patients with increased immunological risk 
(glomerulonephritis, high PRA, re-transplant) were all more likely to be maintained on triple 
therapy.  In contrast, patients with lower eGFRs at 6 months were much more likely to be placed on 
a renal-sparing regimen containing SRL.  CsA use appears to be common in a selected group of 
centers, with average variation of 5-fold in expected use across centers after accounting for patient 
and donor characteristics.  Likelihood of use of CsA-based and SRL-based regimens declined 
markedly over the study period    
These data provide the first rigorous assessment of ISx regimen with appropriate sample 
size to identify the effect of center practice on utilization after controlling for donor, recipient, and 
transplant characteristics. Examination of this unique database demonstrates marked variation in 
center practice even after adjusting for factors including the use of induction agents, living 
donation, race and ethnicity.  
18
In one prior examination of center level variation in the use of 
corticosteroids, Fu et al. examined utilization and outcomes from OPTN records.  At the time of 
their publication (2008), approximately one-third of recipients were discharged on a steroid 
sparing regimen.  Interestingly, the selective use of steroid-free regimen appeared more effective.  
Compared to centers from which 100% of patients were discharged on a steroid free regiment, 
centers in which only 20-49% of patients were discharged steroid-free had fewer deaths (OR 0.73) 
and graft failures (OR 0.71). Outcomes at these centers, however, were better than outcomes at 
centers that discharged all patients on triple therapy.  This study suggests that tailored use of non-
reference ISx regimens may improve patient outcomes.( , 19) 
In contrast with prior studies of ISx use reported to the OPTN, the current study is based on 
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at intermittent survey points.  The use of pharmacy claims to assess ISx regimens has been 
previously validated based on comparisons to electronic medical records and the OPTN registry.  
While the concordance between all three data sources was excellent at one year for CNIs (99-
100%), the claims were somewhat more accurate in determining the use of MMF and AZA.(20, 21) 
Comparison of a large electronic pharmacy claims database with written prescriptions found 
negligible error rates of 0.02% for drug dispensed (22).  Lau, et al. (23) and Boethius, et al. (24) 
independently found pharmacy records and claims to have near-perfect agreement with home 
inventories. However, physician-directed dose changes that are communicated without written 
prescriptions will be missed. Further, while the absence of pharmacy claim for any drug is 
interpreted as no use in this design, alternative explanations may include noncompliance of use 
from an uncaptured “over-supply”.  Our study database also lacked drug levels as a measure of drug 
exposure. Although nothing is more accurate than an audit of patients’ households (25), such data 
collection is expensive, intrusive, and difficult to accomplish on a large scale. 
 Our study was limited to the regimens used at in the first 2 years post-transplant. It is 
certainly possible that ISx management may be changed after the second post-transplant 
anniversary; however, the majority of the early conversation trials (e.g. Spare the Nephron) 
recommend conversion within the first year and late corticosteroid withdrawal has been associated 
with higher rates of rejection than early withdrawal (26).  In the current study, regimen selection 
remained stable between years 1 and 2 in the majority of patients, especially those on triple 
therapy, SRL-based, and CsA-based regimens.   
Clearly, there are also clinical conditions that are not captured in OPTN data that impact the 
choice of ISx after kidney transplant.  For example, patients with a history of CNI-induced 
thrombotic microangiopathy, severe CNI neurotoxicty or nephrotoxicity may be more likely to 
receive SRL-based therapy. As supported by our findings, early acute rejection episodes may result 
in increased intensity of ISx. 
 In conclusion, we found that despite an increasing body of literature which informs the 
tailoring of ISx therapy on the basis of patient characteristics, ISx choice remains largely driven by 
center practice.  Overall, clinically expected patient and donor characteristics were associated with 
ISx choice (e.g. highly-sensitized patients were more commonly treated with triple therapy); 
Patients receiving ISx through trials rather than pharmacy fills also 
cannot be identified through our study data, although some of the patients in the “other” category 
were likely managed under study protocols. Finally, the years of data collection in our study ended 
in 2010, and ongoing research is needed to evaluate the use and trends of recently approved agents 
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however, case factors explained less than 6% of the national variation in practice in our study. 
Center choice explains up to nearly half of observed variation in regimen use.  Further research 
including collaborative clinical trials and secondary data analyses of contemporary practice are 
needed to determine the relationship between center practice, post-transplant outcome, and 
patient selection to advance from a “one size fits all” to a personalized medicine approach to ISx. 
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shown in orange). Overall percentage of regimen use at patient-level across centers: 
Tac+MPA/AZA+Pred, 33.8%; Tac+MPA/AZA (No Pred), 25.8%; Tac without MPA/AZA, 11.3%; SRL-
based, 9.9%; CSA-based, 7.8%; and other regimens, 11.6%. CSA, Cyclosporine; ISx, 
immunosuppression; MPA/AZA, mycophenolate acid; Pred, prednisone; Tac, tacrolimus. 
 
 
Red bar demonstrates national average rate of use of each regimen (within pair-wise regimen 
comparisons).  Each red dot represents adjusted use at one center and the blue bars reflect 95% 
confidence intervals (CI) for use at the center determined by Empirical Bayes Estimates, adjusting 
for case factors of recipients at the center; exclusion of the national average by a 95% CI reflects 
adjusted center use significantly above or below the national average.  
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 Comparison of donor and recipient characteristics from patient in the pharmacy claims data 






( )  
 % % 
Recipient age (years)                        ‡ 
      <18 5.47 4.9 
      18 to 30 9.4 9.32 
      31 to 45 21.77 21.22 
      46 to 59 38.69 37.53 
      >=60 24.68 27.04 
Gender  * 
      Male  60.13 61.11 
      Female 39.87 38.89 
Recipient race  ‡ 
      White 59.06 52.97 
      African American 22.08 25.36 
      Other 18.86 21.67 
ESRD duration  ‡ 
      None (pre-emptive) 19.33 17.45 
      >0 to 24 months 33.43 31.04 
      25 to 60 months 28.87 30.82 
      >60 months 16.67 19.1 
      Missing 1.69 1.59 
Body Mass Index, kg/m2  ‡ 
      <18.5 5.1 4.54 
      18.5 to 25 33.08 32.64 
      25 to 30 32.14 32.4 
      >30 29.04 29.44 
      Missing 0.65 0.97 
Cause of ESRD  ‡ 
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      Glomerulonephritis 21.2 21.09 
      Hypertension 20.94 22.53 
      Polycystic kidney disease 9.39 8.66 
      Other 26.86 24.97 
Recipient Comorbidities  ‡ 
Diabetes 30.85 32.45 
Hypertension 53.92 52.16‡ 
Coronary disease/angina 3.59 3.52 
COPD 0.98 0.95 
Cerebral vascular disease 1.87 1.65* 
Peripheral vascular disease 3.8 3.56 
Highest level of education  † 
Grade school 6.55 6.9 
High school 38.08 38.17 
Some college or higher 38.94 39.61 
Unknown 16.43 15.32 
 
T . Comparison of donor and recipient characteristics from patient in the 
pharmacy claims data sample (PCD Study Sample) and OPTN patients not included in the sample  
 
Employment status  ‡ 
Working 29.98 28.15 
Not working 52.03 55.64 
Unknown 17.98 16.21 
Insurance type  ‡ 
Public 56.02 60.58 
Private 43.80 38.94 
Other/unknown 0.17 0.47 
Previous transplant  * 
Yes 13.12 13.76 
No 86.88 86.24 
Peak PRA level  ‡ 
<10 70.27 68.04 
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>=80 7.9 8.05 
Missing 4.19 5.28 
HLA mismatches  † 
Zero A, B, and DR 10.47 9.9 
Zero DR 46.32 45.79 
Other 43.21 44.31 
Transplant year  ‡ 
2005 19.49 19.81 
2006 22.46 19.72 
2007 22.4 18.99 
2008 20.22 19.61 
2009 15.43 21.87 
Donor race  ‡ 
White 71.05 68.26 
Black 12.42 13.26 
Other 16.54 18.48 
Donor Gender   
Male 52.51 53.09 
Female 47.49 46.91 
CMV sero-pairing  ‡ 
Recipient-, Donor- 17.2 15.55 
Recipient+, Donor- 21.57 21.82 
Recipient-, Donor+ 17.39 16.96 
Recipient+, Donor+ 37 38.72 
Not reported 6.84 6.95 
Donor type  ‡ 
Standard criteria deceased 50.51 53.13 
Expanded criteria deceased 9.38 10.22 
Living related 24.55 22.08 
Living unrelated 15.56 14.57 
P-values: * P 0.02–0.04; † P 0.0001–0.01; ‡ P < 0.0001 
COPD, chronic obstructive pulmonary disease; CMV, cytomegalovirus; ESRD, end-stage 
renal disease; OPTN, Organ Procurement and Transplantation Network; PCD, pharmacy 
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Association of recipient and donor characteristics with immunosuppression regimen from multi-level model including center 
effects for ISx regimen vs. reference regimen (Tacrolimus+MPA/AZA+Prednisone)  
   S -  C -   
 aOR (95% CI) 
  
<18 0.67 (0.52-0.86)† 1.13 (0.84-1.52) 0.77 (0.53-1.13) 0.42 (0.27-0.66)‡ 0.70 (0.52-0.95)* 
18-30 0.91 (0.78-1.07) 0.89 (0.72-1.10) 0.98 (0.77-1.24) 0.55 (0.40-0.74)‡ 0.90 (0.74-1.09) 
31-45 Reference Reference Reference  Reference 
46-59 1.06 (0.95-1.19) 1.20 (1.04-1.39) † 1.11 (0.94-1.31) 1.43(1.19-1.71) ‡ 1.16 (1.02-1.33)* 
>=60 
1.09 (0.96-1.25) 1.50 (1.28-1.76) ‡ 1.12 (0.93-1.37) 1.87 (1.53-2.30) 
‡ 
1.10(0.95-1.29) 
 0.98 (0.90-1.07) 0.87 (0.78-0.97) † 0.90 (0.79-1.03) 0.93 (0.81-1.07) 0.93 (0.84-1.03) 
  
White Reference Reference Reference Reference Reference 
Black 0.90 (0.80-1.03) 1.00 (0.86-1.17) 0.98 (0.82-1.17) 0.69 (0.56-0.86)† 0.93 (0.80-1.07) 
Other 0.93 (0.81-1.06) 0.91 (0.77-1.07) 0.76 (0.62-0.94) † 0.98 (0.80-1.21) 0.91 (0.78-1.07) 
  
Diabetes Reference Reference Reference Reference Reference 
Glomerulonephritis 0.80 (0.70-0.92)† 0.82 (0.69-0.97)* 1.03 (0.84-1.26) 0.97 (0.79-1.19) 0.88 (0.75-1.02) 
Hypertension 0.96 (0.84-1.10) 0.90 (0.77-1.06) 1.21 (0.99-1.48) 0.98 (0.80-1.21) 0.99 (0.85-1.15) 
Polycystic kidney    
Disease 
1.16 (0.98-1.37) 1.00 (0.81-1.23) 1.23 (0.96-1.59) 0.98 (0.75-1.28) 0.95 (0.78-1.16) 
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0.49 (0.41-0.56)‡ 0.74 (0.63-0.88)† 0.81 (0.67-0.99)* 0.61 (0.48-0.77)‡ 0.81 (0.69-0.99)† 
  
None 1.04 (0.92-1.17) 1.14 (0.98-1.32) 1.18 (0.99-1.41) 0.95 (0.78-1.17) 1.12 (0.97-1.29) 
0-24 Reference Reference Reference  Reference Reference 
25-60 0.95 (0.85-1.06) 0.97 (0.84-1.12) 1.05 (0.89-1.25) 0.94 (0.78-1.13) 1.12 (0.98-1.28) 
>60 0.87 (0.75-1.00) 1.06 (0.89-1.26) 1.17 (0.95-1.43) 1.13 (0.91-1.42) 1.25(1.06-1.47)† 
Missing 1.01 (0.73-1.40) 1.17 (0.80-1.71) 1.30 (0.83-2.06) 1.16 (0.69-1.95) 1.06 (0.72-1.59) 
  
   Zero A, B, and DR Reference Reference Reference  Reference Reference 
Zero DR 0.69 (0.60-0.80)‡ 0.96 (0.79-1.16) 0.76(0.61-0.95)* 0.67 (0.53-0.83)‡ 0.74 (0.62-0.87)‡ 
. Association of recipient and donor characteristics with immunosuppression regimen from multi-level model including 
center effects for ISx regimen vs. reference regimen (Tacrolimus+MPA/AZA+Prednisone) 
Other 0.69(0.60-0.80)‡ 1.04 (0.86-1.26) 0.83(0.67-1.04) 0.65 (0.52-0.82)‡ 0.78 (0.66-0.92)† 
  
<10 Reference Reference Reference Reference Reference 
10-79 0.84 (0.75-0.94)† 0.92 (0.80-1.06) 0.95 (0.80-1.12) 0.91 (0.76-1.10) 0.86 (0.75-0.99)* 
>=80 0.58 (0.49-0.70)‡ 0.80 (0.65-0.99)* 0.61(0.47-0.78)‡ 0.51(0.38-0.69)‡ 0.77 (0.63-0.93)† 
Missing 0.99 (0.78-1.27) 0.82 (0.60-1.11) 0.58 (0.39-0.87)† 0.89 (0.59-1.34) 0.80 (0.59-1.09) 
  
Under weight 1.12 (0.92-1.38) 1.03 (0.80-1.32) 0.82 (0.59-1.12) 1.20 (0.85-1.68) 0.97 (0.75-1.26) 
Normal weight Reference Reference Reference Reference Reference 
Over weight 1.00 (0.90-1.12) 0.90 (0.79-1.03) 0.93 (0.80-1.08) 1.02 (0.87-1.20) 1.05 (0.93-1.18) 
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Missing 0.96 (0.59-1.56) 0.85 (0.46-1.58) 0.65 (0.27-1.60) 0.72 (0.28-1.84) 0.92 (0.52-1.62) 
 1.03 (0.93-1.14) 0.91 (0.80-1.03) 0.95 (0.81-1.10) 0.98 (0.83-1.15) 0.90 (0.80-1.01) 
 
 
Grade school 1.04 (0.86-1.26) 0.94 (0.74-1.19) 0.87 (0.65-1.16) 0.92 (0.68-1.23) 0.88 (0.69-1.12) 
High school 0.96 (0.87-1.05) 0.87 (0.77-0.98)* 1.00 (0.86-1.15) 0.98 (0.83-1.14) 1.02 (0.91-1.14) 
College & higher Reference Reference Reference Reference Reference 
Unknown 0.98 (0.86-1.13) 0.99 (0.84-1.17) 1.08 (0.89-1.33) 0.91 (0.73-1.14) 1.20(1.02-1.40)* 
  
2005 Reference Reference Reference Reference Reference 
2006    0.85 (0.74-0.97)* 0.83 (0.71-0.97)* 0.53 (0.44-0.63)‡ 0.56 (0.46-0.67)‡ 0.86 (0.74-0.99)* 
2007    0.86 (0.75-0.98)* 0.72 (0.61-0.85)‡ 0.35 (0.29-0.42)‡ 0.44 (0.36-0.54)‡ 0.73 (0.62-0.85) 
2008 0.97 (0.84-1.12) 0.87 (0.73-1.03) 0.31 (0.25-0.39)‡ 0.40 (0.32-0.50)‡ 0.85 (0.72-1.00) 
2009 0.97 (0.83-1.14) 0.92 (0.76-1.11) 0.29 (0.23-0.37)‡ 0.34 (0.26-0.44)‡ 0.98(0.82-1.17) 
 0.94 (0.86-1.02) 1.03 (0.93-1.14) 1.05 (0.93-1.19) 0.97 (0.85-1.11) 1. 01(0.92-1.12) 
  
SCD Reference Reference Reference Reference Reference 
ECD 0.88 (0.75-1.03) 1.12 (0.94-1.34) 1.73 (1.40-2.13)‡ 0.94 (0.74-1.18) 1.17 (0.98-1.40) 
LRD 1.34 (1.19-1.51)‡ 0.89 (0.77-1.03) 1.16 (0.98-1.39) 0.98 (0.81-1.19) 1.11 (0.97-1.28) 
LUD 1.01 (0.89-1.17) 0.86 (0.73-1.01) 0.95 (0.78-1.17) 0.75(0.60-0.94)† 0.99 (0.84-1.15) 
 
 
 Association of recipient and donor characteristics with immunosuppression regimen from multi-level model including 
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White Reference Reference Reference Reference Reference 
Black 0.98 (0.85-1.13) 1.07 (0.90-1.26) 0.96 (0.78-1.17) 1.06 (0.83-1.35) 1.01 (0.86-1.19) 
Other 1.01 (0.89-1.15) 1.27 (1.09-1.48)† 0.89 (0.73-1.08) 1.07 (0.88-1.31) 1.00 (0.86-1.16) 
      
Cash 1.43 (1.18-1.74)‡ 1.73 (1.37-2.20)‡ 1.11 (0.82-1.50) 1.00 (0.75-1.33) 1.69 (1.36-2.09)‡ 
Medicaid 1.18 (0.98-1.42) 0.92 (0.73-1.17) 0.75 (0.57-0.99)* 0.91 (0.67-1.25) 0.70 (0.54-0.91)† 
Third Party 1.07 (0.97-1.18) 1.34 (1.19-1.51)‡ 1.13 (0.98-1.30) 1.03 (0.88-1.21) 1.25 (1.12-1.40)‡ 
 1.42(1.26-1.60)‡ 1.23(1.07-1.42)† 1.21(1.01-1.45)* 0.88(0.73-1.07) 1.01 (0.88-1.16) 
 0.83(0.73-0.96)† 0.85(0.72-0.99)* 1.13(0.93-1.37) 1.05(0.85-1.29) 1.21(1.05-1.41)† 
 0.39 (0.32-0.47) ‡ 0.92 (0.76-1.11) 1.09 (0.88-1.35) 0.64(0.49-0.83) † 1.08 (0.91-1.28) 
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68 (27.9%) 60 (24.6%) 
 
243 
31 (12.8%) 27 (11.1%) 
-  
241 
61 (25.3%) 33 (13.7%) 
CSA-  
242 
64 (26.4%) 19 (7.9%) 
 
246 
33 (13.4%) 31 (12.6%) 
*Constructed from pairwise comparisons of regimen of interest versus reference regimen (Tac+MPA/AZA+Pred) 
CSA, Cyclosporine; ISx, immunosuppression; MPA/AZA, mycophenolate acid; Pred, prednisone; Tac, tacrolimus. 
 





 239 48 (20.1%) 39 (16.3%) 
 
238 17 (7.1%) 18 (7.6%) 
-  240 47 (19.6%) 18 (7.5%) 
CSA-  236 48 (20.3%) 11 (4.7%) 
 240 18 (7.5%) 16 (6.7%) 
*Constructed from pairwise comparisons of regimen of interest versus reference regimen (Tac+MPA/AZA+Pred) 
CSA, Cyclosporine; ISx, immunosuppression; MPA/AZA, mycophenolate acid; Pred, prednisone; Tac, tacrolimus. 
 


























+M  0.30 3.11 0.30 3.14 0.05 
 
0.16 2.10 0.15 2.08 0.04 
-  0.40 4.16 0.42 4.42 0.04 
-  0.46 5.02 0.47 5.15 0.06 
  0.14 2.03 0.15 2.06 0.02 
Proportion of variance in hierarchical model is equal to the Intraclass Correlation Coefficient, ICC.  
MOR, Median Odds Ratio 
 
CSA, Cyclosporine; ISx, immunosuppression; MPA/AZA, mycophenolate acid; Pred, prednisone; Tac, tacrolimus.  
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